Even in India, early access to innovator brands like Novo Nordisk Ozempic and Wegovy (both semaglutide), plus Rybelsus, Victoza, and Trulicity, meant bills of 10,00020,000 per month for many patients, putting these drugs out of reach for the average middle-class household

Medical professionals have identified five distinct forms of pancreatitis in Ozempic users, each carrying different prognoses: Acute Pancreatitis : The most common form, affecting 80% of cases, characterized by sudden inflammation that typically resolves but can trigger lasting motility disorders with mortality rates below 2% in mild cases Necrotizing Pancreatitis : Occurring in 20-30% of severe cases, involving tissue death within the pancreas that increases the risk of permanent gastroparesis, with mortality rates ranging from 15-30% Hemorrhagic Pancreatitis : A severe variant specifically mentioned in FDAs 2025 updated warnings, involving bleeding within the pancreas and carrying mortality rates exceeding 30% Chronic Pancreatitis : Progressive inflammation leading to permanent scarring and dysfunction, strongly associated with persistent gastroparesis development The FDAs January 2025 update to the ozempic warning label specifically added warnings about fatal and non-fatal hemorrhagic or necrotizing pancreatitis and other serious adverse events including anterior ischemic optic neuropathy, acknowledging the serious nature of these complications

Int J Nanomed 17:10651090 Khurana S, Gourie-Devi M (2025) A Narrative Review of Community-Based Epidemiological Studies on Parkinsons Disease in India
Since Carnitine is naturally present in breast milk, it is generally considered safe in typical amounts
The 6-month lifestyle program requirement is waived under the CV pathway